Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women

Table 4 Comparison of median and inter quartile range (IQR) of day 7 LF median plasma concentration between different genotype groups in pregnant women with uncomplicated Plasmodium falciparum infection using Kruskal–Wallis ANOVA

	Plasma lumefantrine concertation at day 7
	n	Median (IQR)	P value
No of CYP2B61* allele
Zero	17	650.0 (285.8–1603.2)	0.85
One	37	671.6 (280.0–1935.3)
Two	28	672.0 (350.0–2161.8)
CYP3A41B*
1A/1A	3	294.6 (270.0–319.2)	0.24
1A/1B	38	689.7 (354.1–1935.3)
1B/1B	51	644.6 (280.0–2615.0)
No of CYP3A51* allele
Zero	27	716.6 (340.9–2109.4)	0.039
One	47	689.7 (280.0–3059.1)
Two	18	354.2 (285.8–1603.2)
ABCB1 c.4036AG
AA	54	585.2 (330.0–2615.0)	0.28
AG	26	710.7 (282.3–2161.8)
GG	12	1055.1 (285.8–2109.4)

No of CYP2B6*1 allele: two, *1/*1; one, heterozygous for *6 or *18; zero, homozygous for *6 or *18 or combination thereof
No of CYP3A5*1 allele: two, *1/*1; one, heterozygous for *3, *6 or *7; zero, homozygous for *3, *6 or *7, combination thereof

ISSN: 1475-2875